712 related articles for article (PubMed ID: 25682074)
1. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Wong-Brown MW; Meldrum CJ; Carpenter JE; Clarke CL; Narod SA; Jakubowska A; Rudnicka H; Lubinski J; Scott RJ
Breast Cancer Res Treat; 2015 Feb; 150(1):71-80. PubMed ID: 25682074
[TBL] [Abstract][Full Text] [Related]
2. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
4. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
5. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
8. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
9. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
10. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
[TBL] [Abstract][Full Text] [Related]
11. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
[TBL] [Abstract][Full Text] [Related]
13. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
14. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
15. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
16. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
[TBL] [Abstract][Full Text] [Related]
17. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
[TBL] [Abstract][Full Text] [Related]
18. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
20. [BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer].
Ma ZP; Wang W; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):397-400. PubMed ID: 27256048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
